{
    "nctId": "NCT00286117",
    "briefTitle": "ITA - Clinical Study Comparing ARIMIDEX\u2122 With NOLVADEX\u2122 in Women With Breast Cancer Treated With NOLVADEX for at Least 2 Years",
    "officialTitle": "An Open Randomised Clinical Study Comparing ARIMIDEX\u2122 With NOLVADEX\u2122 as Adjuvant Therapies in Post-Menopausal Women With Breast Cancer Already Being Treated With NOLVADEX for at Least Two Years",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 448,
    "primaryOutcomeMeasure": "The primary objective of this analysis was to assess the difference in disease-free survival between post-menopausal women with hormone receptor-positive early breast cancer who switched from tamoxifen to anastrozole and those who continued on tamoxifen",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Post-menopausal status; age \u226475 years;\n* histologically confirmed invasive breast cancer with metastases in the axillary lymph nodes;\n* oestrogen receptor status positive or unknown;\n* primary treatment (surgery +/- radiotherapy, +/- chemotherapy) completed\n\nExclusion Criteria:\n\n* Clinical evidence of metastatic disease (including local or remote recurrence, even if the patient appeared to be in complete remission at the time of randomisation).",
    "sex": "FEMALE",
    "minimumAge": "N/A",
    "stdAges": "CHILD, ADULT, OLDER_ADULT"
}